S100A7 promotes lung adenocarcinoma to squamous carcinoma transdifferentiation, and its expression is differentially regulated by the Hippo-YAP pathway in lung cancer cells

Rui Wang¹, Yunguang Li¹, Enze Hu¹, Fei Kong¹, Junhao Wang¹, Jin Liu¹, Qirui Shao¹, Ying Hao², Dacheng He¹, Xueyuan Xiao¹

¹Key Laboratory of Cell Proliferation and Regulation Biology, Ministry of Education, College of Life Science, Beijing Normal University, Beijing, China
²The Department of Basic Theory, College of Sports, Northwest Normal University, Lanzhou, China

Correspondence to: Xueyuan Xiao, email: xyxiao@bnu.edu.cn

Keywords: S100A7, lung cancer cells, ADC to SCC transdifferentiation, YAP, the Hippo pathway

Received: October 19, 2016 Accepted: January 09, 2017 Published: February 03, 2017

Copyright: Wang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC-BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Our previous study revealed that S100A7 was selectively expressed in lung squamous cell carcinoma tissues but not in adenocarcinoma. Thus far, the functions of S100A7 in lung cancer have remained largely unknown. Here, we reveal that S100A7 overexpression facilitates the transdifferentiation from adenocarcinoma (ADC) to squamous carcinoma (SCC) in several lung cancer cells, which is confirmed by an increase in DNp63 expression and a decrease in thyroid transcription factor 1 (TTF1) and aspartic proteinase napsin (napsin A) expression. Further study finds that activation of the Hippo pathway induces S100A7 expression and further confirms that nuclear YAP acts as a repressor of S100A7 in H292 cells. Subsequently, we verify that TEAD1 is required for YAP transcriptional repression of S100A7. More importantly, we determine that S100A7 overexpression partially rescues lung ADC to SCC transdifferentiation inhibited by YAP overexpression in all tested cells, suggesting that S100A7 and YAP have the opposite effects on lung ADC to SCC conversion. Taken together, our study demonstrates for the first time that S100A7 not only functions as a facilitator of adenous-squamous carcinoma phenotypic transition in lung cancer cells but also that its expression is differentially regulated by the Hippo-YAP pathway.

INTRODUCTION

Human lung cancer is the leading cause of worldwide cancer-related mortality, and the incidence is progressively increasing in China. Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) are two major groups of lung cancers, and the former further comprises adenocarcinoma (ADC), squamous cell carcinoma (SCC) and large cell carcinoma [1, 2, 3]. However, lung ADC and SCC are considered to arise from different epithelial cells in the lung. Accordingly, lung ADC mainly expresses TTF1 and napsin A, whereas lung SCC expresses DNp63 and cytokeratin 5/14 [4, 5]. Interestingly, adenosquamous carcinoma (mixed ADC and SCC) has been frequently observed in single lesions of human lung tumors, suggesting a monoclonality and a potential lineage transition between these two subtypes [6]. Although the precise mechanism of lineage correlation or dynamic transition between human lung ADC and SCC remains largely unknown, recent reports have provided direct evidence to support ADC to SCC transdifferentiation in Lkb1-deficient mouse models of human lung cancer [6, 7].

S100A7 belongs to the S100 multigenic family of calcium-modulated proteins of the EF-hand type and was originally identified in psoriatic keratinocytes [8, 9, 10, 11, 12]. Subsequent studies have shown that upregulation of S100A7 is detected in nearly all types of SCC tissues as well as adenocarcinomas of the breast [13, 14, 15, 16, 17]. Our previous study showed that S100A7 was selectively expressed in lung SCC and large cell carcinoma tissues but not in ADC specimens [18, 19]. We further confirmed that S100A7 could be dramatically
induced in several SCC cells and xenografts and acted as a dual regulator in promoting proliferation and suppressing squamous differentiation [20, 21]. However, little is known about how and why S100A7 induction occurs in lung cancer cells. Thus, understanding the mechanisms of S100A7 induction in lung cancer might have important implications for S100A7-targeted therapies.

The Hippo pathway was initially identified in Drosophila and is an important regulator of organ size through its tight control of cell growth and proliferation [22]. At the core of this pathway in mammals is a kinase cascade consisting of MST1/2 and LATS1/2. When the Hippo pathway is activated, MST1/2 phosphorylates the hydrophobic motif of LATS1/2 (LATS-HM) and activates LATS1/2 [23], which in turn directly phosphorylate YAP (Yes-associated protein) at serine 127 (YAP-S127) [24, 25, 26, 27]. The phosphorylation of YAP-S127 is inactivated through its cytoplasmic retention. Conversely, inactivation of the Hippo pathway leads to YAP nuclear translocation and downstream target gene expression through the binding of YAP to TEADs (the TEAD/TEF family transcription factors), the primary transcription factor partners of YAP, resulting in cell survival and proliferation [26, 27, 28, 29]. Recently, the Hippo pathway has also been found to regulate cell fate determination. For example, YAP inhibited squamous transdifferentiation of Lkb1-deficient lung adenocarcinoma through ZEB2-dependent DNp63 repression [7]. Moreover, our recent findings showed that YAP repressed S100A7 induction in A431 cells through activation of the Hippo pathway [29]. Therefore, it would be interesting to investigate the relationships and functions of YAP and S100A7 in other cancers, such as lung cancer.

Here, we verify that S100A7 acts as a facilitator of adenous-squamous phenotypic transition in lung cancer cells. We further demonstrate that S100A7 is not only induced by activation of the Hippo pathway but also that its overexpression partially rescues squamous differentiation inhibited by YAP overexpression in several lung cancer cells. Collectively, our findings may provide new insight into our understanding of the molecular basis of lung ADC to SCC transdifferentiation.

RESULTS
S100A7 promotes adenocarcinoma to squamous carcinoma transdifferentiation in lung cancer cells

Our previous study revealed that S100A7 was selectively expressed in lung SCC tissues but not in ADC tissues. Recent reports regarding lung ADC to SCC phenotypic transition in an Lkb1 (Liver kinase B1 or Serine-Threonine Kinase 11, STK 11) -deficient mouse model caught our attention [6]. To investigate whether S100A7 was involved in this transition process in lung cancer cells, three lung adenocarcinoma cell lines (H292, A549, and H1299 cells) were selected. Although the H292 cell line is a mucoepidermoid pulmonary carcinoma cell line that belongs to one subtype of adenocarcinoma, it expresses multiple markers of squamous differentiation according to the ATCC. Additionally, we found that H292 cells could express...
S100A7, but A549 and H1299 cells did not. Considering the expression levels of S100A7 in the different cell lines, we first depleted S100A7 in H292 cells (Figure 1A). Indeed, the SCC marker DnP63 was significantly downregulated, and the adenocarcinoma markers TTF1 and napsin A were markedly upregulated (Figure 1B), suggesting that silencing of S100A7 attenuated lung ADC to SCC transdifferentiation. Next, we found that overexpression of S100A7 inversely promoted this transition in the same cells (Figure 1C and 1D). Strikingly, introduction of S100A7 into A549 and H1299 cells also facilitated ADC to SCC conversion (Figure 1E, 1F, 1G and 1H). These results indicate that S100A7 has a promoting effect on ADC to SCC transdifferentiation in lung cancer cells.

**S100A7 is negatively regulated by YAP through activation of the Hippo pathway**

A recent study showed that overexpression of YAP inhibited ADC to SCC transdifferentiation of human lung cancer in an Lkb1-deficient mouse model, whereas knockdown of YAP facilitated squamous transdifferentiation [7]. Together, the above results and the inhibitory effect of YAP on S100A7 expression in A431 cells [30] gave us reason to speculate that YAP most likely functions as a repressor of S100A7 in H292 cells. To test this, we depleted YAP expression in H292 cells using specific siRNA. As expected, single depletion of YAP was sufficient to induce the expression of S100A7 mRNA and protein, and the efficiency of YAP knockdown was also confirmed by a decrease in CTGF (Connective tissue growth factor) and CYR61 (Cysteine-rich angiogenic inducer 61) expression (Figure 2A and 2B). Conversely, the constitutively active YAP mutant YAP-S127A and YAP-WT markedly inhibited S100A7 expression in the same cells, and the former had a greater effect on S100A7 repression than the latter (Figure 2C and 2D), suggesting that nuclear YAP is a repressor of S100A7 expression in H292 cells. However, S100A7 induction was not detected in A549 and H1299 cells with YAP knockdown (Figure 2E).
and 2F), suggesting that additional genetic or epigenetic changes were also required for S100A7 induction in these cells. We further found that knockdown of LATS1 and MST1 rescued the inhibitory effect of YAP on S100A7 expression in suspended or densely cultured H292 cells (Figure 3A, 3B, 3C and 3D), whereas overexpression of LATS1 led to an increase in S100A7 expression and YAP phosphorylation (Figure 3E and 3F). Together, our data unequivocally demonstrate that activation of the Hippo pathway represses S100A7 expression in H292 cells.

**F-actin disruption promotes S100A7 expression and YAP phosphorylation**

Cell suspension and dense culture also lead to activation of the Hippo pathway through actin cytoskeleton remodeling in several cell lines [31, 32]. To investigate whether F-actin cytoskeletal reorganization participated in S100A7 expression and YAP phosphorylation in H292 cells, two F-actin cytoskeleton-disrupting reagents, latrunculin B (Lat B) and cytochalasin D (Cyto D), were used. Lat B and Cyto D disrupt the F-actin cytoskeleton by preventing actin polymerization and by capping filament plus ends, respectively [33]. As expected, abrogation of F-actin polymerization by Lat B resulted in S100A7 induction and YAP phosphorylation in a time- and dose-dependent manner (Figure 4A and 4B), suggesting that F-actin integrity plays a critical role in the control of S100A7 expression and YAP activity in H292 cells. Similar results were also observed in the same cells after Cyto D treatment (Figure 4C). S100A7 expression and YAP inactivation were also confirmed by qPCR (Figure 4D). Unsurprisingly, neither Lat B nor Cyto D treatment resulted in S100A7 induction in A549 or H1299 cells (Figure 4E, 4F, 4G and 4H). To further confirm whether F-actin plays an important role in S100A7 induction, we knocked down Cofilin1 (CFL1), Gelsolin (GSN) and CAPZB together in attached H292 cells using their specific siRNAs (Figure 4I, 4J and 4K) and then cultured cells in suspension and dense for two days. As expected, S100A7 induction was significantly blocked and YAP-S127 was also markedly decreased in silenced cells compared with control cells (Figure 4L and 4M). Taken together, these data support the notion that reorganization of the actin cytoskeleton plays an important role in S100A7 induction through activation of the Hippo pathway.

**Figure 3: S100A7 is negatively regulated by YAP through activation of the Hippo pathway.** H292 cells were transfected with MST or Lats1 siRNAs, and the cells were then cultured in suspension A, or dense culture C, for 48 h. The expression of YAP, pYAP-S127 and S100A7 was detected by Western blotting. The expression of S100A7, CYR61 and CTGF was determined by real-time PCR B, D. Overexpression of LATS1 in H292 cells; an anti-Flag tag antibody was used to judge the transfection efficiency. The expression of YAP, pYAP-S127, S100A7, CYR61 and CTGF was examined by Western blotting E, or real-time PCR F. GAPDH was used to assess equal loading. *p < 0.05, **p < 0.01; t-test versus the experimental groups and the control groups.
TEAD1 is indispensable for YAP-repressed S100A7 induction

YAP does not have DNA-binding activity, and TEADs have emerged as one of the main partners of YAP binding to DNA to stimulate or repress YAP-dependent gene expression [34]. To investigate whether a TEAD was a YAP co-activator for S100A7 induction, we knocked down the expression of TEAD1/2/3/4 individually in H292 cells. Interestingly, transient depletion of TEAD1 alone was sufficient to induce S100A7 expression and inhibit CTGF and CYR61 expression (Figure 5A and 5B). Unexpectedly, knockdown of TEAD 2/3/4 did not facilitate S100A7 induction (Figure 5C and 5D). To further confirm this result, we overexpressed YAP-WT and YAP-S94A in H292 cells because YAP-S94A, unlike wild-type YAP and YAP-S127A, is defective in TEAD1 binding [35]. As expected, we found that S100A7 was marginally decreased by YAP-S94A overexpression compared with the control cells (Figure 5E and 5F), indicating that YAP inhibited S100A7 expression through interaction with TEAD1. Taken together, we conclude that TEAD1 functions as the transcriptional cofactor of YAP to repress S100A7 expression in H292 cells.

S100A7 partially rescues lung ADC to SCC transdifferentiation inhibited by YAP overexpression

Considering that S100A7 was inhibited by YAP and that the opposite effects of YAP and S100A7 were observed on lung ADC to SCC transition, we next explored the role of YAP in mediating S100A7 function during ADC to SCC transdifferentiation. We first performed experiments involving single depletion or overexpression of YAP in H292 cells. As expected, overexpression of YAP led to severe downregulation of S100A7 and DNp63 but significant upregulation of TTF1.

Figure 4: F-actin disruption promotes S100A7 expression and YAP phosphorylation. H292 cells were treated with Lat B (20 μg/ml) for different lengths of time A, and at different doses B. H292 cells were also treated with Cyto D (0.05 μM) for 48 h C., and the expression of total YAP, p-YAP and S100A7 was examined by Western blotting. The expression of S100A7, CYR61 and CTGF was determined by real-time PCR D. A549 and H1299 cells were also treated with Lat B (20 μg/ml) for 24 h E, F, and Cyto D (0.05 μM) G, H. for 48 h. The expression of total YAP, p-YAP and S100A7 was examined by Western blotting, and H292 cells served as a positive control. The silencing efficiency of CLF, GSN and CAPZB was examined by real-time PCR I, J, K. H292 cells were transfected with CLF, GSN and CAPZB siRNAs, and the cells were then cultured in suspension L, or dense culture M. for 48 h; the expression of LATS, pLATS, YAP, pYAP-S127 and S100A7 was detected by Western blotting. GAPDH was used to assess equal loading. **p < 0.01; t-test versus the experimental groups and the control groups.
and napsin A, whereas depletion of YAP alone inversely inhibited this transition in H292 cells (Figure 6A, 6B, 6C and 6D). To test whether this effect of YAP was cell-line specific, we also performed the same treatment in A549 and H1299 cells. Unsurprisingly, similar results were obtained in A549 cells (Figure 6E, 6F, 6G and 6H) and H1299 cells (Figure 6I, 6J, 6K and 6L), except with regard to S100A7. Strikingly, these results were consistent with reports that YAP overexpression or knockdown regulated lung ADC to SCC transdifferentiation in Lkb1-deficient mice [7]. Next, we performed a double depletion of S100A7 and YAP in H292 cells (Figure 7A). Interestingly, the combined abrogation of YAP and S100A7 showed the same tendency as the single removal of YAP but displayed weaker effects than single removal of YAP in H292 cells (Figure 7B), implying that YAP had a stronger influence on lung ADC to SCC transdifferentiation than S100A7. Strikingly, S100A7 overexpression partially overcame the inhibition of squamous transdifferentiation imposed by YAP overexpression in H292 cells (Figure 7C and 7D). Importantly, similar results were also obtained when both S100A7 and YAP were overexpressed in A549 (Figure 7E and 7F) and H1299 cells (Figure 7G and 7H). These data collectively provide evidence that S100A7 plays an important role in the initiation of squamous reprogramming downstream of YAP.

**DISCUSSION**

Phenotypic transition or phenotypic plasticity is an important feature of tumors arising in various organs. Notably, multiple lines of evidence from previous studies...

---

**Figure 5: TEAD1 is indispensable for YAP-mediated S100A7 repression.** Knockdown of TEAD1 using siRNA in H292 cells A. The expression of TEAD1, S100A7, CYR61 and CTGF was determined by real-time PCR B. Knockdown of TEAD2, TEAD3, and TEAD4 using specific siRNAs in H292 cells. The expression of S100A7 was determined by Western blotting C. the silencing efficiency of TEAD2/3/4 was examined by real-time PCR D. H292 cells were transfected with YAP-WT and YAP-S94A plasmids. Then, the cells were cultured in suspension for 48 h, and the expression of YAP, pYAP-s127 and S100A7 was detected by Western blotting E. The expression of S100A7, CYR61 and CTGF was determined by real-time PCR F. GAPDH was used to assess equal loading. **p < 0.01; t-test versus the experimental groups and the control groups.
have demonstrated that lung cancer cells are capable of carrying out lineage transition of cancer types or subtypes and thus exhibit phenotypic plasticity [1, 2, 3]. It has been reported that Nkx2-1 deletion in neoplastic lung tissue causes conversion to a gastric lineage [36]. The transition from a neuroendocrine to a mesenchymal phenotype can also be achieved by ectopic expression of oncogenic Ras \(^{\text{V12}}\) in SCLC [37]. A recent study revealed the genotypic and histological transition of EGFR-mutant NSCLC into SCLC after targeted therapy [38]. Lung ADC with Lkb1 deficiency can progressively transdifferentiate into SCC, and depletion of YAP significantly accelerates this transition [6, 7]. Here, we demonstrated that S100A7 not only promotes lung ADC to SCC transdifferentiation in several lung cancer cells but also that its expression is differentially regulated by the Hippo-YAP pathway. Lung ADC with Lkb1 deficiency can progressively transdifferentiate into SCC, and depletion of YAP significantly accelerates this transition [6, 7]. Here, we demonstrated that S100A7 not only promotes lung ADC to SCC transdifferentiation in several lung cancer cells but also that its expression is differentially regulated by the Hippo-YAP pathway. Lung ADC with Lkb1 deficiency can progressively transdifferentiate into SCC, and depletion of YAP significantly accelerates this transition [6, 7]. Here, we demonstrated that S100A7 not only promotes lung ADC to SCC transdifferentiation in several lung cancer cells but also that its expression is differentially regulated by the Hippo-YAP pathway. Lung ADC with Lkb1 deficiency can progressively transdifferentiate into SCC, and depletion of YAP significantly accelerates this transition [6, 7]. Here, we demonstrated that S100A7 not only promotes lung ADC to SCC transdifferentiation in several lung cancer cells but also that its expression is differentially regulated by the Hippo-YAP pathway. Lung ADC with Lkb1 deficiency can progressively transdifferentiate into SCC, and depletion of YAP significantly accelerates this transition [6, 7]. Here, we demonstrated that S100A7 not only promotes lung ADC to SCC transdifferentiation in several lung cancer cells but also that its expression is differentially regulated by the Hippo-YAP pathway. Lung ADC with Lkb1 deficiency can progressively transdifferentiate into SCC, and depletion of YAP significantly accelerates this transition [6, 7]. Here, we demonstrated that S100A7 not only promotes lung ADC to SCC transdifferentiation in several lung cancer cells but also that its expression is differentially regulated by the Hippo-YAP pathway. Lung ADC with Lkb1 deficiency can progressively transdifferentiate into SCC, and depletion of YAP significantly accelerates this transition [6, 7]. Here, we demonstrated that S100A7 not only promotes lung ADC to SCC transdifferentiation in several lung cancer cells but also that its expression is differentially regulated by the Hippo-YAP pathway. Lung ADC with Lkb1 deficiency can progressively transdifferentiate into SCC, and depletion of YAP significantly accelerates this transition [6, 7]. Here, we demonstrated that S100A7 not only promotes lung ADC to SCC transdifferentiation in several lung cancer cells but also that its expression is differentially regulated by the Hippo-YAP pathway. Lung ADC with Lkb1 deficiency can progressively transdifferentiate into SCC, and depletion of YAP significantly accelerates this transition [6, 7]. Here, we demonstrated that S100A7 not only promotes lung ADC to SCC transdifferentiation in several lung cancer cells but also that its expression is differentially regulated by the Hippo-YAP pathway. Lung ADC with Lkb1 deficiency can progressively transdifferentiate into SCC, and depletion of YAP significantly accelerates this transition [6, 7]. Here, we demonstrated that S100A7 not only promotes lung ADC to SCC transdifferentiation in several lung cancer cells but also that its expression is differentially regulated by the Hippo-YAP pathway. Lung ADC with Lkb1 deficiency can progressively transdifferentiate into SCC, and depletion of YAP significantly accelerates this transition [6, 7]. Here, we demonstrated that S100A7 not only promotes lung ADC to SCC transdifferentiation in several lung cancer cells but also that its expression is differentially regulated by the Hippo-YAP pathway. Lung ADC with Lkb1 deficiency can progressively transdifferentiate into SCC, and depletion of YAP significantly accelerates this transition [6, 7]. Here, we demonstrated that S100A7 not only promotes lung ADC to SCC transdifferentiation in several lung cancer cells but also that its expression is differentially regulated by the Hippo-YAP pathway. Lung ADC with Lkb1 deficiency can progressively transdifferentiate into SCC, and depletion of YAP significantly accelerates this transition [6, 7]. Here, we demonstrated that S100A7 not only promotes lung ADC to SCC transdifferentiation in several lung cancer cells but also that its expression is differentially regulated by the Hippo-YAP pathway. Lung ADC with Lkb1 deficiency can progressively transdifferentiate into SCC, and depletion of YAP significantly accelerates this transition [6, 7]. Here, we demonstrated that S100A7 not only promotes lung ADC to SCC transdifferentiation in several lung cancer cells but also that its expression is differentially regulated by the Hippo-YAP pathway. Lung ADC with Lkb1 deficiency can progressively transdifferentiate into SCC, and depletion of YAP significantly accelerates this transition [6, 7]. Here, we demonstrated that S100A7 not only promotes lung ADC to SCC transdifferentiation in several lung cancer cells but also that its expression is differentially regulated by the Hippo-YAP pathway.

Figure 6: S100A7 and YAP have opposite effects on lung ADC to SCC transdifferentiation in lung cancer cells. Following the ectopic expression YAP-S127A or knockdown of YAP in H292 cells, the expression of YAP, DNp63 and TTF-1 was examined by Western blotting A, C, and the expression of YAP, napsin A, TTF-1 and DNp63 was detected by real-time PCR B, D. Single silencing of YAP or overexpression of YAP-S127A in A549 E, G, or H1299 cells I, K, the expression of YAP, napsin A, TTF-1 and DNp63 was detected by Western blotting. The expression of YAP, napsin A, TTF-1 and DNp63 was examined by real-time PCR F, H, J, L. **p < 0.01; t-test versus the YAP experimental groups and the control groups.
ADC and SCC are two distinct subtypes of lung cancer with different morphologies and different gene expression signatures. The transcription factor Nkx-2/TTF1 has emerged as a candidate regulator of lung adenocarcinoma differentiation and is expressed in 75-85% of human lung adenocarcinomas [6, 7, 39, 40]. Napsin A is an aspartic proteinase expressed in the lung and kidney.

Among the three proteins currently used as markers for lung adenocarcinoma, TFF1 showed the same sensitivity (84.6%) as napsin A for adenocarcinoma, whereas surfactant protein-A and surfactant protein-B showed lower sensitivities. Moreover, napsin A showed the highest specificity (94.3%) for adenocarcinoma in non-small cell lung carcinoma [39, 40]. However, DNp63 is a marker of

Figure 7: Ectopic expression of S100A7 partially rescues lung ADC to SCC transdifferentiation inhibited by YAP overexpression in lung cancer cells. Following double depletion or the combined overexpression of S100A7 and YAP in H292 cells, the expression of S100A7, YAP, TTF-1 and DNp63 was examined by western blotting A, C, and the expression of napsin A, TTF-1 and DNp63 was determined by real-time PCR B, D. The combined overexpression of YAP and S100A7 in A549 cells E, and H1299 cells G. The transfection efficiency of both was examined by Western blotting. The expression of napsin A, TTF-1 and DNp63 was determined by real-time PCR F, H. GAPDH was used to assess equal loading. GAPDH assessed equal loading. *p < 0.05; t-test versus the experimental groups and the control groups.
that active differentiation programs may influence Hippo-YAP regulation. Moreover, we speculate in lung cancer cells but also elicits a distinct response not only facilitates ADC to SCC transdifferentiation in lung cancer phenotypic plasticity during tumor progression. Our data also imply that the microenvironment of cancer cells might influence cellular plasticity and subtype transdifferentiation during metastasis.

**MATERIALS AND METHODS**

**Cell culture**

The human adenocarcinoma carcinoma cell lines H292, A549 and H1299 were purchased from the Chinese Academy of Sciences Committee Type Culture Collection Cell Bank and were authenticated by short tandem repeat analysis at HK Gene Science Technology Co. (Beijing, China). All cells were cultured according to the corresponding culture methods of the ATCC. Cell suspension cultures were obtained as described in our previous studies [11]. H292 cells were transfected with the indicated siRNAs simultaneously and then were cultured under suspension conditions for two days before the cells were harvested for western blotting.

**Western blotting**

Western blotting analysis was performed as previously described [19]. The following antibodies were used: S100A7 (1/1000; Abcam, ab13680); YAP (1/500, Santa Cruz, sc-101199); pYAP (S127) (1/1000; Cell Signaling Technology, 13008S); anti-Flag tag (CWBiO, CW0287A); and anti-His tag (MBL, D291-3). GAPDH (ZSGB-BIO, TA-08) was used as a loading control.

**Reverse transcription and real-time PCR**

Real-time PCR was performed on an ABI 7300 Real-time PCR System (Applied Biosystems) using Power SYBR Green PCR Master Mix (Applied Biosystems, Forster City, CA, USA) in a final volume of 20 μl. GAPDH was used as an endogenous control for each sample. The primers used for each of the genes are listed [Supplementary Table 1 and Supplementary Table 2].

**Plasmids and reagents**

The pcDNA4-His-YAP WT and S127A vectors and the pcMV14-Flag-YAP WT and S94A vectors were kindly provided by Dr. Zhang (Mayo Clinic College of Medicine, USA). For pcMV14-Flag-LATS1, the LATS1 (NCBI Gene ID: 9113) cDNA fragment was amplified using 5’-CGGGTACCATGAAGGAGGATGAAAAG-3’ and 5’-GCTCTAGAATCTAGATCGCGATTT-3’ and was then cloned into the mammalian expression vector pcMV4 (Invitrogen, Carlsbad, CA, USA) using the KpnI and XbaI restriction enzymes (Takara). Latrunculin B (L5288) and cytochalasin D (C8273) were purchased from Sigma.

Plasmids and reagents

![Plasmids and reagents](image-url)
Statistical analysis

Statistical analysis was performed using GraphPad Prism software. Statistical significance was evaluated using Student’s t-test (2-tailed) to compare two groups of data. The asterisks indicate significant differences between the experimental groups and the corresponding control condition. Differences were considered statistically significant at P-values of less than 0.05. P-values <0.05 and <0.01 are indicated with one and two asterisks, respectively.

ACKNOWLEDGMENTS

We thank Dr. Jinsan Zhang from Mayo Clinic College of Medicine for kindly providing us with the pcDNA4-His-YAP WT; S127A and pCMV14-Flag-YAP WT; S94A vectors.

CONFLICTS OF INTEREST

The Authors do not have any conflicts of interest.

GRANT SUPPORT

This work was supported by the National Natural Science Foundation of China (81172216, 81272604), of the Ministry of Science and Technology of China (2011CB915504).

REFERENCES

1. Minna JD, Roth JA, Gazdar AF. Focus on lung cancer. Cancer Cell. 2002; 1:49–52.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007; 57:43–66.
3. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH, and Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346:92–98.
4. Sutherland KD, Berns A. Cell of origin of lung cancer. Mol Oncol. 2010; 4:397–403.
5. Meeussen R, Berns A. Mouse models for human lung cancer. Genes Dev. 2005; 19:643–64.
6. Han X, Li F, Fang Z, Gao Y, Li F, Fang R, Yao S, Sun Y, Li L, Zhang W, Ma H, Xiao Q, Ge G, et al. Transdifferentiation of lung adenocarcinoma in mice with Lkb1 deficiency to squamous cell carcinoma. Nat Commun. 2014; 5:3261–4261.
7. Gao Y, Zhang W, Han X, Li F, Wang X, Wang R, Fang Z, Tong X, Yao S, Li F, Feng Y, Sun Y, Hou Y, et al. YAP inhibits squamous transdifferentiation of Lkb1-deficient lung adenocarcinoma through ZEB2-dependent DNp63 repression. Nat Commun. 2014; 5:4629.
8. Kulski JK, Lim CP, Dunn DS, Bellgard M. Genomic and phylogenetic analysis of the S100A7 (Psoriasin) gene duplications within the region of the S100 gene cluster on human chromosome 1q21. J Mol Evol. 2003; 56:397–406.
9. Madsen P, Rasmussen HH, Jefferies H, Honore B, Dejgaard K, Olsen E, Kiil J, Walbom E, Andersen AH, Basse B, Lauridsen JB, Ratz GP, Celis A, et al. Molecular cloning, occurrence, and expression of a novel partially secreted protein “psoriasin” that is highly up-regulated in psoriatic skin. J Invest Dermatol. 1991; 97:701–12.
10. Hoffmann HJ, Olsen E, Etzerodt M, Madsen P, Thøgersen HC, Kruse T, Celis JE. Psoriasin binds calcium and is upregulated by calcium to levels that resemble those observed in normal skin. J Invest Dermatol. 1994; 103:370–75.
11. Donato R. Intracellular and extracellular roles of S100 proteins. Microsc Res Tech. 2003; 60:540–51.
12. Watson PH, Leygue ER, Murphy LC. Psoriasin (S100A7). Int J Biochem Cell Biol. 1998; 30:567–71.
13. Nasser MW, Qamri Z, Deol YS, Ravi J, Powell CA, Trikha P, Schwendener RA, Bai XF, Shilo K, Zou X, Leone G, Wolf R, Yuspa SH, et al. S100A7 enhances mammary tumorigenesis through upregulation of inflammatory pathways. Cancer Res. 2012; 72:604–15.
14. Mandal S, Curtis L, Pind M, Murphy LC, Watson PH. S100A7 (psoriasin) influences immune response genes in human breast cancer. Exp Cell Res. 2007; 313:3016–25.
15. Kesting MR, Sudhoff H, Hasler RJ, Nieberler M, Pautke C, Wolf KD, Wagenpfeil S, Al-Benna S, Jacobsen F, Steinstraesser L. Psoriasin (S100A7) up-regulation in oral squamous cell carcinoma and its relation to clinicopathologic features. Oral Oncol. 2009; 45:731–36.
16. Tripathi SC, Matta A, Kaur J, Grigull J, Chauhan SS, Thakar A, Shukla NK, Duggal R, DattaGupta S, Railhan R, Siu KW. Nuclear S100A7 is associated with poor prognosis in head and neck cancer. PLoS One. 2010; 5:e11939.
17. Barbieri MR, Andrade CD, Silva WA Jr, Marques AA, Leopoldino AM, Montes MB, Dias-Baruffi M, Soares IC, Nakamura M, Alves VA, Laure PJ, Zago MA, Greene L. Expression of human protein S100A7 (psoriasin), preparation of antibody and application to human larynx squamous cell carcinoma. BMC Res Notes. 2011; 4:494.
18. Zhang H, Wang Y, Chen Y, Sun S, Li N, Lv D, Liu C, Huang L, He D, Xiao X. Identification and validation of S100A7 associated with lung squamous cell carcinoma metastasis to brain. Lung Cancer. 2007; 57:37–45.
19. Zhang H, Zhao Q, Chen Y, Wang Y, Gao S, Mao Y, Li M, Peng A, He D, Xiao X. Selective expression of S100A7 in lung squamous cell carcinomas and large cell carcinomas but not in adenocarcinomas and small cell carcinomas. Thorax. 2008; 63:352–59.
20. Li T, Qi Z, Kong F, Li Y, Wang R, Zhang W, Shang Y, Huang L, He D, Xiao X. S100A7 acts as a dual regulator in promoting proliferation and suppressing squamous differentiation through GATA-3/caspase-14 pathway in A431 cells. Exp Dermatol. 2015; 24:342–48.

21. Qi Z, Li T, Kong F, Li Y, Wang R, Wang J, Xiao Q, Zhang W, Sun S, He D, Xiao X. The Characteristics and Function of S100A7 Induction in Squamous Cell Carcinoma: Heterogeneity, Promotion of Cell Proliferation and Suppression of Differentiation. PLoS One. 2015; 10:e0128887.

22. Rybarczyk A, Wierzbicki P, Kowalczyk A, Kmieć Z. [Role of the Hippo pathway in cell proliferation and organ size control. Disorders of the pathway in cancer diseases]. [Article in Polish]. Postepy Hig Med Dosw (Online). 2014; 68:503–15.

23. Halder G, Dupont S, Piccolo S. Transduction of mechanical and cytoskeletal cues by YAP and TAZ. Nat Rev Mol Cell Biol. 2012; 13:591–600.

24. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, Xie J, Ikemoue T, Yu J, Li L, Zheng P, Ye K, Chinnaiyan A, et al. Inactivation of YAP oncprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007; 21:2747–61.

25. Chan EH, Nousiainen M, Chalamalasetty RB, Schäfer A, Nigg EA, Silljé HH. The Ste20-like kinase Mst2 activates the human large tumor suppressor kinase Lats1. Oncogene. 2005; 24:2076–86.

26. Callus BA, Verhagen AM, Vaux DL. Association of mammalian sterile twenty kinases, Mst1 and Mst2, with hSalvador via C-terminal coiled-coil domains, leads to its stabilization and phosphorylation. FEBS J. 2006; 273:4264–76.

27. Hao Y, Chun A, Cheung K, Rashidi B, Yang X. Tumor suppressor LATS1 is a negative regulator of oncogene YAP. J Biol Chem. 2008; 283:5496–509.

28. Zhao B, Li L, Wang L, Wang CY, Yu J, Guan KL. Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev. 2012; 26:54–68.

29. Li Y, Kong F, Wang J, Hu E, Wang R, Liu J, Xiao Q, Zhang W, He D, Xiao X. S100A7 induction is repressed by YAP via the Hippo pathway in A431 cells. Oncotarget. 2016; 7:38133–42. doi: 10.18632/oncotarget.9477.

30. Wada K, Itoga K, Okano T, Yonemura S, Sasaki H. Hippo pathway regulation by cell morphology and stress fibers. Development. 2011; 138:3907–14.

31. Aragona M, Panciera T, Manfrin A, Giulitti S, Michielin F, Elvassore N, Dupont S, Piccolo S. A mechanical checkpoint controls multicellular growth through YAP/TAZ regulation by actin-processing factors. Cell. 2013; 154:1047–59.

32. Vassilev AJ, Kaneko KJ, Shu H, Zhao Y, DePamphilis ML. TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm. Genes Dev. 2001; 15:1229–41.

33. Zhao B, Ye X, Yu J, Li L, Li W, Li S, Yu J, Lin JD, Wang CY, Chinnaiyan AM, Lai ZC, Guan KL. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 2008; 22:1962–71.

34. Basu S, Totty NF, Irwin MS, Sudol M, Downward J. Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol Cell. 2003; 11:11–23.

35. Komuro A, Nagai M, Navin NE, Sudol M. WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. J Biol Chem. 2003; 278:33334–40.

36. Snyder EL, Watanabe H, Magendanz M, Hoersch S, Chen TA, Wang DG, Crowley D, Whittaker CA, Meyerson M, Kimura S, Jacks T. Nkx2-1 represses a latent gastric differentiation program in lung adenocarcinoma. Mol Cell. 2013; 50:185–99.

37. Calbo J, van Montfort E, Proost N, van Drunen E, Beverloo HB, Meuwissen R, Berns A. A functional role for tumor cell heterogeneity in a mouse model of small cell lung cancer. Cancer Cell. 2011; 19:244–56.

38. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S, Cosper AK, Akhavanfard S, Heist RS, Temel J, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011; 3:75ra26.

39. Nishino M, Hoang MP, Della Pelle P, Morales-Oyarvide V, Huynh TG, Mark EJ, Mino-Kenudson M. Napsin A/p40 antibody cocktail for subtyping non-small cell lung carcinoma on cytology and small biopsy specimens. Cancer Cytopathol. 2016; 124:472–84.

40. Mukhopadhyay S, Katzenstein AL. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Am J Surg Pathol. 2011; 35:15–25.

41. Westfall MD, Pietenpol JA. p63: Molecular complexity in development and cancer. Carcinogenesis. 2004; 25:857–64.

42. West NR, Watson PH. S100A7 (psoriasin) is induced by the proinflammatory cytokines oncostatin-M and interleukin-6 in human breast cancer. Oncogene. 2010; 29:2083–92.